BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTC QB: SNTI) reported the administration of SNS01-T to the first patient in cohort 4 of its Phase 1b/2a study in multiple myeloma and non-Hodgkins B-cell lymphoma.
Help employers find you! Check out all the jobs and post your resume.
